N-acetyl Cysteine and Patients With Non-alcoholic Fatty Liver Disease

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Effect of N-acetyl cysteine on markers of oxidative stress and insulin resistance in patients with Non-alcoholic fatty liver disease

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• Males or females aged 18-60 years diagnosed with NAFLD

Exclusion Criteria:

• History of alcohol consumption, drug addiction or the use of medications known to precipitate steatohepatitis.

• Patients with schistosomiasis, active hepatitis B or C, autoimmune and metabolic diseases.

• current Consumption of any antioxidant supplements and hepatotoxic drug.

• Pregnancy or lactation or expecting to get pregnant during the study.

• Medical, psychological, or pharmacological factors interfering with the collection or interpretation of study data.

• Active Cancer patients.

• Anyone having hypersensitivity to N-acetylcysteine.

• Anyone already taking N-acetylcysteine.